Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing
Endpoints
|
July 23, 2026
X min read
Endpoints
|
July 23, 2026
Share on Social
More like this
Media
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
September 2, 2026
Read Now
Press
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
September 2, 2026
Read Now
